Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,500,000 shares, an increase of 5.6% from the March 31st total of 1,420,000 shares. Based on an average daily volume of 124,300 shares, the days-to-cover ratio is currently 12.1 days. Approximately 2.3% of the company’s shares are short sold.

Galapagos Stock Up 3.1 %

GLPG opened at $29.34 on Thursday. Galapagos has a 12 month low of $28.30 and a 12 month high of $45.21. The company has a fifty day simple moving average of $32.45 and a 200 day simple moving average of $36.09. The stock has a market cap of $1.93 billion, a P/E ratio of -12.81 and a beta of 0.24.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Morgan Stanley reissued an “equal weight” rating and issued a $38.00 price target on shares of Galapagos in a research note on Monday, April 22nd. Bank of America reissued an “underperform” rating and issued a $31.00 price target (down previously from $41.00) on shares of Galapagos in a research note on Thursday, March 28th. Finally, StockNews.com downgraded Galapagos from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, Galapagos has an average rating of “Hold” and a consensus price target of $34.50.

Institutional Trading of Galapagos

A number of large investors have recently made changes to their positions in the company. FMR LLC increased its position in shares of Galapagos by 0.7% in the 3rd quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock valued at $149,176,000 after buying an additional 28,497 shares in the last quarter. Stonepine Capital Management LLC increased its position in shares of Galapagos by 17.6% in the 3rd quarter. Stonepine Capital Management LLC now owns 802,544 shares of the biotechnology company’s stock valued at $27,728,000 after buying an additional 119,880 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Galapagos by 1.4% in the 4th quarter. Primecap Management Co. CA now owns 678,877 shares of the biotechnology company’s stock valued at $27,596,000 after buying an additional 9,200 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Galapagos by 3.9% in the 4th quarter. Wellington Management Group LLP now owns 495,217 shares of the biotechnology company’s stock valued at $20,131,000 after buying an additional 18,552 shares in the last quarter. Finally, Hudson Bay Capital Management LP increased its position in shares of Galapagos by 7.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock valued at $12,092,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 32.46% of the company’s stock.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.